Loading, Please Wait...

CST: 11/11/2019 18:43:01   

Rubius Therapeutics to Announce Third Quarter 2019 Financial Results

6 Days ago

CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced plans to report third quarter 2019 financial results on Thursday, November 14, 2019, before market open.

The company will not be conducting a teleconference in conjunction with its financial results press release.
                                                                                                           
About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, or follow us on Twitter and LinkedIn.

Contact:
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
lori.melancon@rubiustx.com

Media Contact: 
Dan Budwick
1AB.
+1 (973) 271-6085
dan@1abmedia.com

 

Is your business listed correctly on America’s largest city directory network of 1,000 portals?